Editas Medicine

EDIT NASDAQ
25.64
+0.28
+1.10%
After Hours: 25.64 0 0.00% 17:58 08/16 EDT
Open
25.59
Prev Close
25.36
High
26.06
Low
25.44
Volume
690.86K
Avg Vol (3M)
680.29K
52 Week High
33.80
52 Week Low
17.80
% Turnover
1.40%
Market Cap
1.27B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Editas Medicine EDIT stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).
MORE >

Recently

Name
Price
%Change